Free tool
FAERS Monitor: Juxtapid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203858 or its brand name (Juxtapid, Lomitapide Mesylate). Reports on generic versions are filed under their own applications.
Reports
3,782
Serious
1,231
33% of reports
Hospitalization
389
Death reported
94
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea1,076
- weight decreased844
- therapy cessation792
- nausea558
- abdominal pain upper287
- abdominal discomfort242
- flatulence242
- vomiting219
- off label use208
- fatigue206
- hepatic enzyme increased188
- drug dose omission184
- inappropriate schedule of drug administration184
- constipation169
- abdominal pain166
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 86 |
| 2014 | 551 |
| 2015 | 1,346 |
| 2016 | 316 |
| 2017 | 327 |
| 2018 | 343 |
| 2019 | 169 |
| 2020 | 193 |
| 2021 | 137 |
| 2022 | 78 |
| 2023 | 76 |
| 2024 | 64 |
| 2025 | 61 |
| 2026 | 35 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,377 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapy cessationSignal | 792 | 87.1 | 81.9 | 66,472 |
| flatulenceSignal | 242 | 23.8 | 21.1 | 5,262 |
| weight decreasedSignal | 844 | 16.9 | 15.9 | 12,708 |
| hepatic enzyme increasedSignal | 188 | 15.4 | 13.4 | 2,514 |
| inappropriate schedule of drug administrationSignal | 184 | 14.4 | 12.5 | 2,286 |
| diarrhoeaSignal | 1,076 | 9.3 | 8.8 | 8,183 |
| abdominal discomfortSignal | 242 | 8.0 | 7.1 | 1,493 |
| abdominal pain upperSignal | 287 | 7.8 | 6.9 | 1,698 |
| drug dose omissionSignal | 184 | 6.2 | 5.4 | 802 |
| constipationSignal | 169 | 4.3 | 3.7 | 431 |
| abdominal painSignal | 166 | 4.0 | 3.4 | 370 |
| nauseaSignal | 558 | 3.9 | 3.6 | 1,259 |
| vomitingSignal | 219 | 2.6 | 2.3 | 217 |
| fatigue | 206 | 1.5 | 1.3 | 32 |
| off label use | 208 | 1.3 | 1.2 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.